The state of diabetes research in the UK
Diabetes UK estimates that around 4.9 million people in the United Kingdom live with diabetes, and most of them have type 2. The condition touches nearly every family in some way, from the grandparent who needles their finger before dinner to the parent quietly tracking carbs at a school play. Behind that everyday routine sits a busy research network that most people never see.
What has changed recently is how visible that network has become. Commercial research delivery centres, set up through NHS trusts, now recruit patients directly through hospital websites and national registries. Hospitals in Bradford, Birmingham, Bristol, Newcastle and Belfast are running international studies that would once have been confined to a handful of academic centres. The result is that joining a trial no longer means travelling to London or hoping a consultant remembers to mention it.
The opportunities are broad. One ongoing phase 2 study, sponsored by Eli Lilly, is comparing an investigational medicine against placebo in people with type 2 diabetes who are already on a stable dose of a GLP-1 treatment, with sites in Birmingham, Blackpool, Bristol, Bromborough and Newcastle. A separate phase 3 AstraZeneca study is recruiting adults with type 2 diabetes and reduced kidney function to test a new medicine called Elecoglipron alongside their existing treatment. Meanwhile, the Bradford and West Yorkshire Commercial Research Delivery Centre has opened two trials examining a potential treatment for weight loss and blood sugar control, one arm for people with type 2 diabetes and one for those without.
Three frustrations tend to come up again and again when patients talk about research. The first is timing: a medicine can look exciting on the news but take years to reach the NHS formulary, so trials feel like the only way to get near it. The second is confusion. Registry entries are written for researchers, not for the person reading them in a kitchen at ten o'clock at night. The third is geography, because availability still varies by region even though the system is improving.
What a good trial actually looks like
Not every study is a drug trial. Some of the most useful current research focuses on devices and daily support, which is often where people feel the biggest practical wins.
A real-world study published by researchers in the UK tracked a socioeconomically diverse group of adults with poorly controlled diabetes who used the Dexcom ONE continuous glucose monitoring system. Over the follow-up period, participants showed meaningful improvements in HbA1c and reported greater confidence in managing their condition. The encouraging detail for patients is that this was not a small group of highly motivated volunteers. It was a broad cross-section, and the results held.
That theme continues in an ongoing ISRCTN-registered study testing Dexcom ONE+ in primary care settings across the UK and Ireland. The idea is simple: if continuous glucose monitoring helps people who inject insulin, why wait for a specialist referral? Researchers want to find out whether starting it in general practice improves blood sugar control and patient satisfaction. For anyone with type 2 diabetes on insulin, this type of diabetes clinical trial for insulin users is worth watching closely.
There are also options that have nothing to do with needles. A four-week digital programme from the University of the West of England in Bristol is recruiting adults with type 1 or type 2 diabetes to test a self-guided online course built on psychological and behaviour-change techniques, with the goal of reducing diabetes distress. In Northern Ireland, Ulster University is exploring whether omega-3 supplements can slow the progression of type 2 diabetes in people with a BMI between 25 and 50. These studies matter because they treat diabetes as a whole-person condition, not just a blood test.
A comparison of current UK research options
| Study or programme | Main focus | Format | Good fit for | Advantages | Considerations |
|---|
| Eli Lilly LY3457263 (phase 2) | New medicine on top of GLP-1 therapy | In-person, multiple UK cities | People with type 2 diabetes already on semaglutide or tirzepatide | Access to a novel treatment early | Placebo-controlled, longer commitment |
| AstraZeneca Elecoglipron (phase 3) | New medicine for diabetes plus kidney issues | In-person, phase 3 sites | Adults with type 2 diabetes and reduced kidney function | Large international study, well supported | Participants continue dapagliflozin |
| Bradford obesity and blood sugar trials | Weight loss and glycaemic control | In-person, Bradford | People with obesity, with or without type 2 diabetes | Dual benefit on weight and glucose | Recruitment limited to the region |
| Dexcom ONE+ in primary care | Continuous glucose monitoring | Starts in GP practice | People with type 2 diabetes on insulin | Earlier access to CGM technology | Availability depends on local sites |
| UWE Bristol digital programme | Emotional wellbeing | Online, self-guided | Adults with type 1 or type 2 diabetes | No travel, flexible timing | Needs four weeks of commitment |
| Ulster University omega-3 study | Dietary supplement and progression | In-person, Coleraine | People with prediabetes or type 2 diabetes, BMI 25-50 | Simple intervention, close monitoring | Attendance at the study unit required |
In most UK trials, participants do not pay for the investigational treatment or the extra study visits, and many teams arrange travel reimbursement. Exact arrangements vary, so it is worth asking the research nurse before you agree to anything. Eligibility is always determined by the study team, and you can step away at any point without it affecting your usual NHS care.
How to find a trial that suits you
Searching for the right opportunity is easier than it used to be. The NHS runs a public service called Be Part of Research that lists studies by condition and location, which is a sensible starting point if you want to type in your postcode and see what is nearby. Diabetes UK also maintains a clinical trials page that is updated regularly, with plain-English summaries written for patients rather than scientists.
A practical approach for the busy reader:
- Ask your GP or diabetes nurse first. They know your history and can flag whether a study is clinically sensible for you, and many trials ask for a clinician to support your referral.
- Search for a diabetes research study near me using the Be Part of Research and ClinicalTrials.gov registries, then filter by your region.
- Read the plain English summary, not the protocol. If one is not provided, email the contact listed and ask.
- Check the time commitment. Some studies need one visit; others run for two years with regular check-ins.
- Confirm travel arrangements before you sign. Reimbursement policies differ, and you want to know the practical cost before you start.
A patient in Bradford who joined one of the new commercial research studies described it as the first time she had felt properly supported with her weight and blood sugar together. Her routine had been the same for years, and the structured appointments gave her something the clinic never had time for: a clear plan and someone to answer questions between visits. That sense of being looked after is common in trial feedback, and it is worth remembering alongside the medical outcomes.
What happens after you join
Once you are in, the day-to-day is far less dramatic than the word trial suggests. You attend scheduled visits, follow the instructions given, and continue any treatment your doctor has prescribed. Your existing care does not stop, and the study team keeps in touch with your usual NHS team throughout. If you decide the study is not for you, you leave, and nobody holds it against you.
The bigger picture is worth holding on to. Every person who takes part in a diabetes management trial helps shape what the NHS will offer in a few years, whether that is a new medicine for people with kidney complications, a simpler way to monitor glucose, or a digital tool that eases the mental load of a lifelong condition.
If you have type 2 diabetes and have wondered whether research is something other people do, it is not. The studies described here are actively recruiting in 2026, and the teams running them are open to first-time participants. A conversation with your diabetes team about what is available in your area is a small step that could change how you manage your condition, and it costs nothing but half an hour. Even if you decide not to join, knowing what is out there gives you something valuable: options.
研究の知恵